Galectin-9 (Gal-9), a soluble lectin playing a major role in innate and adaptive immunity, was found to be correlated with the PD-L1, PD-1, FOXP3, CD3, CD4, and CD8 levels in SCLC patients. This evidence concerns the gene CD8A and small cell lung carcinoma.